和鉑醫藥(02142.HK)與丹娜法伯癌症研究院合作開發新型生物療法
和鉑醫藥-B(02142.HK)公佈,公司已與丹娜-法伯癌症研究院訂立一項爲期多年、涉及多方面的研究合作協議,以共同開發癌症治療的新型生物療法。
公司科學家與丹娜-法伯研究者將共同開發新型腫瘤藥物,包括雙特異性抗體及CAR-T細胞產品。近年來,雙特異性抗體及CAR-T細胞療法均被視爲腫瘤免疫學領域的新一代解決方案。雙特異性抗體因具有結合兩種不同靶標的能力,可望擴展單克隆抗體(mAb)療法的可能性,而CAR-T細胞療法爲一種創新的免疫療法,使用經特別重組的T細胞,將其重新定向以靶向癌細胞。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.